şüŔęĘÓƵ

Vanderbilt researchers have developed a new method to analyze mutations in blood stem cells that can trigger explosive, clonal expansions of abnormal cells.

The Vanderbilt School of Nursing has been approved for a $250,000 award that will support identifying and disseminating strategies for overcoming barriers to patient- and family-centered comparative effectiveness research with patients who are critically ill and hospitalized in an intensive care unit setting.

An international consortium co-led by Vanderbilt's Rubén Martínez-Barricarte has discovered a new genetic disorder that causes immunodeficiency and profound susceptibility to opportunistic infections including a life-threatening fungal pneumonia. 

The laboratories of Brian Bachmann and Jonathan Irish have developed a method to discover new small molecules that may kill cancer cells by working through the body’s immune system. Read More

Nashville Biosciences LLC and Illumina Inc. today announced an agreement with Amgen to whole-genome sequence approximately 35,000 DNA samples.

By determining how proteins in different areas of the eye’s lens change over time, Vanderbilt researchers have learned more about how they could contribute to the mysterious progression of cataracts—a clouding of the lens that affects more than 65 million people worldwide each year.   Read More

Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.

College of Arts and Science faculty members Nathan Schley, Allison Walker, and John Yang have each been awarded grants from the National Institutes of Health to continue their groundbreaking chemistry research. The faculty members are conducting big-picture research with practical applications in a variety of health contexts—including drug synthesis, biomolecular conversion, and disease treatment.

Vanderbilt researchers in the lab of Erin Calipari, assistant professor of pharmacology and molecular physiology and biophysics, have demonstrated a role for dopamine signaling in novelty-based learning—a finding that could have major impacts on how neurological diseases are treated. Read More

Vanderbilt investigators have discovered a molecular mechanism that promotes chronic kidney disease following kidney injury.

An international team of investigators has found that mild to moderate reduction in kidney function may cause cardiovascular disease, even in people without symptoms of heart disease or diabetes.

A Vanderbilt study found that higher levels of excess oxygen given to patients under general anesthesia add risk of injury to the kidneys, lungs and heart.

Researchers in the Vanderbilt University School of Medicine have received three grants totaling $13.6 million from the National Institutes of Health to develop molecular “atlases” of the brain, kidney, eye and other tissues.

An in-depth analysis by Vanderbilt investigators of published research studies supports removing race from the calculation of estimated glomerular filtration rate (eGFR) — an assessment of kidney function.

Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.

Warren Center for Neuroscience Drug Discovery lead researchers discover a therapy that may treat memory loss and slow the progression of Alzheimer’s disease. Read More

Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.

The School of Medicine Basic Sciences Dean’s Lecture featured renowned immunologist, virologist, and alumnus Dr. Barney S. Graham. In his talk, “Reflections on Pandemics and the Future of Medicine,” Graham discussed his early research experiences leading up to his seminal work on the first experimental COVID-19 vaccines, along with his observations on the pandemic and hopes for the future of medicine.

A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

A team at Case Western Reserve University and Vanderbilt University Medical Center has determined with atomic-level precision how two established drugs bind to and alter the conformation of a cell membrane transporter protein called NKCC1, shutting down its activity.